Tirofiban Superior to Aspirin in Stroke Without Large Occlusion

New research suggests some patients do better with tirofiban than with low-dose aspirin following disabling stroke without a visible large or medium intracranial vessel occlusion.

The study showed a greater percentage of such patients who received intravenous tirofiban had a modified Rankin Scale (mRS) score of 0-1 at 90 days compared with those who got low-dose oral aspirin.

The findings were presented by Wenjie Zi, Department of Neurology, Xinqiao Hospital and Second Affiliated Hospital, Amy Medical University, Chonqing, China, at the International Stroke Congress (ISC) 2023.

Many patients with small vessel stroke suffer disability, but there's currently no proven treatment for them "except early antithrombotic therapy for prevention purposes," he said.

Tirofiban is a highly selective fast-acting, non-peptide glycoprotein (GP) IIb/IIIa platelet receptor inhibitor that has a rapid onset of action and a short half-life (about 2 hours), said Zi. Research shows GP IIb/IIIa antagonists are effective for the treatment of acute coronary syndromes.

Source: MEDspace